• 1
    Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341: 468475.
  • 2
    Walker SM, Pajno GB, Lima MT, Wilson DR, Durham SR. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol 2001;107: 8793.
  • 3
    Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998;102: 508562.
  • 4
    Durham SR, Till SJ. Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998;102: 157164.
  • 5
    Durham SR, Varney VA, Gaga M, Jacobson MR, Varga EM, Frew AJ et al. Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin Exp Allergy 1999;29: 14901496.
  • 6
    Varney VA, Hamid QA, Gaga M, Ying S, Jacobson M, Frew AJ et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993;92: 644651.
  • 7
    Wachholz PA, Durham SR. Induction of ‘blocking’ IgG antibodies during immunotherapy. Clin Exp Allergy 2003;33: 11711174.
  • 8
    Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 1997;27: 11311139.
  • 9
    Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003;111: 12551261.
  • 10
    Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998;102: 98106.
  • 11
    Bousquet J, Lockey R, Malling HJ, Alvarez-Cuesta E, Canonica GW, Chapman MD et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of allergy, asthma and immunology [see comments]. Ann Allergy Asthma Immunol 1998;81: 401405.
  • 12
    Pollock KG, Conacher M, Wei XQ, Alexander J, Brewer JM. Interleukin-18 plays a role in both the alum-induced T helper 2 response and the T helper 1 response induced by alum-adsorbed interleukin-12. Immunology 2003;108: 137143.
  • 13
    Mark A, Bjorksten B, Granstrom M. Immunoglobulin E responses to diphtheria and tetanus toxoids after booster with aluminium-adsorbed and fluid DT-vaccines. Vaccine 1995;13: 669673.
  • 14
    Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm Biotechnol 1995;6: 495524.
  • 15
    Thompson HS, Davies ML, Watts MJ, Mann AE, Holding FP, O'Neill T et al. Enhanced immunogenicity of a recombinant genital warts vaccine adjuvanted with monophosphoryl lipid A. Vaccine 1998;16: 19931999.
  • 16
    Mikloska Z, Ruckholdt M, Ghadiminejad I, Dunckley H, Denis M, Cunningham AL. Monophosphoryl lipid A and QS21 increase CD8 T lymphocyte cytotoxicity to herpes simplex virus-2 infected cell proteins 4 and 27 through IFN-gamma and IL-12 production. J Immunol 2000;164: 51675176.
  • 17
    Baldrick P, Richardson D, Elliott G, Wheeler AW. Safety evaluation of monophosphoryl lipid A (MPL): an immunostimulatory adjuvant. Regul Toxicol Pharmacol 2002;35: 398413.
  • 18
    Moore A, McCarthy L, Mills KH. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine 1999;17: 25172527.
  • 19
    Newman KD, Sosnowski DL, Kwon GS, Samuel J. Delivery of MUC1 mucin peptide by Poly(d,l-lactic-co-glycolic acid) microspheres induces type 1 T helper immune responses. J Pharm Sci 1998;87: 14211427.
  • 20
    Baldridge JR, Yorgensen Y, Ward JR, Ulrich JT. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 2000;18: 24162425.
  • 21
    Thoelen S, Van Damme P, Mathei C, Leroux-Roels G, Desombere I, Safary A et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 1998;16: 708714.
  • 22
    Heppner DG, Gordon DM, Gross M, Wellde B, Leitner W, Krzych U et al. Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes. J Infect Dis 1996;174: 361366.
  • 23
    Stoute JA, Kester KE, Krzych U, Wellde BT, Hall T, White K et al. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J Infect Dis 1998;178: 11391144.
  • 24
    Drachenberg KJ, Heinzkill M, Urban E. Short-term immunotherapy with tree pollen allergoids and the adjuvant monophosphoryl lipid-A – results from a multicentre, placebo-controlled, randomised, double-blind study. Allergologie 2002;25: 466474.
  • 25
    Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001;56: 498505.
  • 26
    Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, Krauth MT, Majlesi Y et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003;33: 11981208.
  • 27
    Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7: 145173.
  • 28
    Wierenga EA, Snoek M, Jansen HM, Bos JD, van Lier RA, Kapsenberg ML. Human atopen-specific types 1 and 2 T helper cell clones. J Immunol 1991;147: 29422949.
  • 29
    Drachenberg KJ, Proll S, Urban E, Woroniecki SR. Short-term immunotherapy using an allergy vaccine adjuvanted with monophosphoryl lipid A: a post-marketing surveillance study. Int Rev Allergol Clin Immuuol 2002;31: 8: No. 4.
  • 30
    Wheeler AW, Marshall JS, Ulrich JT. A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int Arch Allergy Immunol 2001;126: 135139.
  • 31
    De Becker G, Moulin V, Pajak B, Bruck C, Francotte M, Thiriart C et al. The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int Immunol 2000;12: 807815.
  • 32
    Ismaili J, Rennesson J, Aksoy E, Vekemans J, Vincart B, Amraoui Z et al. Monophosphoryl lipid A activates both human dendritic cells and T cells. J Immunol 2002;168: 926932.
  • 33
    Yang QB, Martin M, Michalek SM, Katz J. Mechanisms of monophosphoryl lipid A augmentation of host responses to recombinant HagB from Porphyromonas gingivalis. Infect Immun 2002;70: 35573565.
  • 34
    Stuyt RJ, Netea MG, Geijtenbeek TB, Kullberg BJ, Dinarello CA, Van Der Meer JW. Selective regulation of intercellular adhesion molecule-1 expression by interleukin-18 and interleukin-12 on human monocytes. Immunology 2003;110: 329334.
  • 35
    Martin M, Michalek SM, Katz J. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect Immun 2003;71: 24982507.
  • 36
    Norman PS. Immunotherapy: 1999–2004. J Allergy Clin Immunol 2004;113: 10131023.
  • 37
    Till S, Walker S, Dickason R, Huston D, O'Brien F, Lamb J et al. IL-5 production by allergen-stimulated T cells following grass pollen immunotherapy for seasonal allergic rhinitis. Clin Exp Immunol 1997;110: 114121.
  • 38
    Komai-Koma M, Jones L, Ogg GS, Xu D, Liew FY. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci U S A 2004;101: 30293034.
  • 39
    Drachenberg KJ, Heinzkill M, Urban E, Woroniecki SR. Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents. Allergol Immunopathol (Madr) 2003;31: 270277.